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Abstract
Background: Childhood tuberculosis (TB) patients under India’s Revised National TB Control Programme (RNTCP) are
managed using diagnostic algorithms and directly observed treatment with intermittent thrice-weekly short-course
treatment regimens for 6–8 months. The assignment into pre-treatment weight bands leads to drug doses (milligram per
kilogram) that are lower than current World Health Organization (WHO) guidelines for some patients.
Objectives: The main aim of our study was to describe the baseline characteristics and treatment outcomes reported under
RNTCP for registered childhood (age ,15 years) TB patients in Delhi. Additionally, we compared the reported programmatic
treatment completion rates between children treated as per WHO recommended anti-TB drug doses with those children
treated with anti-TB drug doses below that recommended in WHO guidelines.
Methods: For this cross-sectional retrospective study, we reviewed programme records of all 1089 TB patients aged ,15
years registered for TB treatment from January to June, 2008 in 6 randomly selected districts of Delhi. WHO disease
classification and treatment outcome definitions are used by RNTCP, and these were extracted as reported in programme
records.
Results and Conclusions: Among 1074 patients with records available, 651 (61%) were females, 122 (11%) were ,5 years of
age, 1000 (93%) were new cases, and 680 (63%) had extra-pulmonary TB (EP-TB)—most commonly peripheral lymph node
disease [310 (46%)]. Among 394 pulmonary TB (PTB) cases, 165 (42%) were sputum smear-positive. The overall reported
treatment completion rate was 95%. Similar reported treatment completion rates were found in all subgroups assessed,
including those patients whose drug dosages were lower than that currently recommended by WHO. Further studies are
needed to assess the reasons for the low proportion of under-5 years of age TB case notifications, address challenges in
reaching all childhood TB patients by RNTCP, the accuracy of diagnosis, and the clinical validity of reported programme
defined treatment completion.
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Introduction
Childhood tuberculosis (TB) has traditionally had a lower
priority than adult TB within National TB Programmes (NTPs),
because it is largely non-infectious, cases have been thought to be
few, and the assumption that effective control of adult TB could
prevent childhood TB. In many countries with high TB incidence,
however, childhood TB (i.e., TB among the population aged less
than 15 years) constitutes a significant proportion (approximately
11–14%) of the TB case-load and under-5 mortality [1], [2]. Of
the estimated 9.3 million annual incident TB cases in the world in
the year 2007, at-least 1 million are estimated to be less than 15
years of age [3]. Children are susceptible to infection with M.
tuberculosis in the community, at greater risk of progressing to active
disease when infected at a very young age [4] and there are also
well-documented cases of children acting as a source of infection
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focus on the proper management of childhood TB for the control
of TB.
The World Health Organisation(WHO)and the GlobalStop TB
Partnership have strongly recommended that National TB
Programmes (NTPs) take responsibility for the diagnosis and
treatment of all TB patients, including children [8]. However,
NTPs—especially in resource limited settings—face numerous
challenges in ensuring accurate TB diagnosis along with access to
a supervised, child friendly treatment. Although detection and
isolation of Mycobacterium tuberculosis by culture remains the corner
stone for diagnosis, quality assured diagnostic tests other than
sputum smear microscopy may not be universally available under
theNTPs. This makes the diagnosisofTB inchildrenchallenging as
children most often have pauci-bacillary pulmonary TB resulting in
smear-negative pulmonary TB; and also a higher proportion of
childhood TB presents as extra-pulmonary TB (EP-TB). Standard-
ised anti-TB treatment regimens using the combinations of the first
line anti-TB drugs are recommended for the programmatic
management of TB in children. However concerns have been
expressed over the adequacy of drug dosages [4], [9], [10], [11],
[12]. In addition to these concerns, NTPs also face operational
challenges in ensuring that all diagnosed childhood TB patients are
notified and treated under the programme, addressing issues related
to drug logistic management, and achieving adherence to therapy
for optimal treatment outcomes [13]. Amidst all these challenges,
one of the first things a programme can do is to obtain and evaluate
data already existing within the programme setting to identify
priority areas for programmatic interventions. These include
assessment of case notifications and treatment outcomes, stratified
by age, gender, type and category of TB [14], [15].
India contributes approximately 21% to the global incidence of
TB and shares the largest burden of this disease in the world.
India’s Revised National TB Control Programme (RNTCP), with
a total TB case notification of more than 1.52 million cases,
contributed approximately 24% to the global new and relapse TB
case notifications in the year 2007. The program-defined
treatment success rate among new TB patients registered under
RNTCP in 2007 was more than 85% [3]. In 2008, at the National
level, 79,779 patients (6% of the new cases) registered under
RNTCP were aged less than 15 years [16]. There is, however,
limited information on the basic demographic, clinical character-
istics and programme defined treatment outcomes of these TB
patients [17]. Furthermore, concerns have been raised on the
adequacy of the RNTCP-recommended drug doses, which for
some children on a milligrams per kilogram basis fall below that
recommended by WHO in 2009 [18], [19], [20]. The primary
objective of this exploratory operational research study was to
describe the basic demographic, clinical characteristics and
programme specified treatment outcomes of patients aged ,15
years registered for TB treatment in Delhi. The study also assessed
these treatment outcomes between patients treated with appro-
priate drug doses and those treated with drug doses below that
recommended in WHO 2009 guidelines.
Methods
Study Setting
Delhi State in North India (population of 17.6 million people)
has 24 RNTCP reporting districts with 36 TB units. Under
RNTCP, one TB Unit is a basic programme management unit,
caters to a population of approximately 500,000, and maintains a
separate TB register for each unit. In 2008, a total of 49,905
patients were registered for treatment, of which 38,027 patients
were new cases. Among new cases, 5461 (14.5%) were ,15 years.
Delhi was chosen for this study primarily because the state has the
highest notification rate (32 cases per 100,000 population) of TB
patients aged less than 15 years, in the country when compared to
the National average (7 cases per 100,000 population).
Diagnosis and treatment of TB in Children aged ,15
years under RNTCP
Under RNTCP, Directly Observed Treatment Short-course
(DOTS) is the recommended strategy for treatment of TB. The
case definitions, disease classification, treatment regimens and
treatment outcome definitions used by RNTCP are in line with
standard WHO definitions [21], and are detailed in Table 1. In
order to simplify the diagnosis and treatment of childhood TB,
RNTCP in consultation with the Indian Academy of Paediatrics
(IAP) has described criteria for suspecting TB among children, has
separate algorithms for diagnosing pulmonary smear-positive TB
(Figure 1) and peripheral TB lymphadenitis (Figure 2), and a
strategy for treatment (Table 2) and monitoring patients who are
on treatment (Figure 3) [22].
In brief, TB diagnosis is based on clinical features, smear
examination of sputum where this is available, positive family
history, tuberculin skin testing, chest radiography and histo-
pathological examination as appropriate. The treatment strategy
comprises three key components. First, as in adults, children with
TB are classified, categorised, registered and treated with
intermittent short-course chemotherapy (thrice-weekly therapy
from treatment initiation to completion), given under direct
observation of a treatment provider (DOT provider) and the
disease status is monitored during the course of treatment
(Figure 3). Second, based on their pre- treatment weight, children
are assigned to one of 6 pre-treatment weight bands (,6kgs; 6–
10 Kg; 11–17 Kg; 18–25Kg; 26–30Kg and .30Kgs). Patients
with pre-treatment weight within the range of these individual
weight bands are treated with a corresponding pre-fixed weight
band dosage made available in individual patient-wise boxes.
Patients weighing less than 6kg are treated with individualized
dosages, and those weighing more than 30 Kg are treated using
adult dosages. Third, uninterrupted good quality anti-TB drugs
through ‘‘ready-to-use’’ patient wise boxes containing the patients’
complete course of anti-TB drugs are made available to every
registered TB patient according to programme guidelines [23].
TB is suspected in children seeking health care for their ailment
by the treating physicians/paediatricians who may work in the
public or non-public health centres. The RNTCP strongly
recommends (although it is not mandatory) that these treating
physicians/paediatricians both in the public and non-public sector
should suspect, diagnose and treat childhood TB according to
programme guidelines. There is a need for referral of diagnosed
TB patients by the treating medical practitioners for the TB
patients to get registered under the RNTCP and get into the
RNTCP records and reports. If for any reason the TB cases are
not referred to the programme then all such patients are not
registered under the programme and are ‘missed’ in the
notification system.
Study population
All patients aged ,15 years registered for TB treatment under
RNTCP from 1
st Jan, 2008 to 30
th June 2008 in Delhi.
Study design and sample size
We used a descriptive cross-sectional study design with
retrospective review of existing programme records. Cluster
Childhood TB in Delhi, India
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were included. The sample size was calculated for estimating
programme defined ‘‘favourable’’ treatment outcomes (cured and
treatment completed) with 95% confidence levels, with an absolute
precision of 63%. A sample size of 993 paediatric TB patients was
calculated based on a) the overall proportion of successful
treatment outcomes reported in Delhi during this period across
all age groups (88%), b) the design effect of 2 for the cluster-
sampling approach, and c) a 10% expected non-availability of
information. RNTCP reporting districts (24 in number) were
selected as the cluster unit. Expecting an average of 160 TB
patients aged ,15 years in each district from Jan–June, 2008, 6
clusters were randomly selected, with selection probabilities
weighted by the Population Proportionate to the Size (PPS)
sampling technique.
Source of information, study variables and definitions
The sources of information were two RNTCP records namely,
the TB register and treatment cards. The variables included:
demographic (age and sex), clinical (disease classification, type of
TB, site of EP-TB, pre-treatment weight) and treatment related
(categorisation, treatment regimens, drug dosages, DOT provider
type and location, treatment outcomes). We defined a ‘‘low
milligram per kilogram body weight group’’ consisting of those
patients whose treatment doses for isoniazid were below current
WHO 2009 recommendations [19], [20], meaning those patients
whose pre-treatment weights were at the upper end of the
respective weight bands described above, i.e. 9–10 kg, 16–17 kg,
24–25 kg, or 29–30 kg. For the purpose of this study, all
definitions are as per RNTCP definitions. Most of these cases
would have also received lower than recommended dosages for
other co-administered drugs as well.
Program defined outcomes were classified as ‘completed’ (which
also includes cured) and ‘others’ (which includes deaths, default,
failures, transferred out and not-recorded).
Data entry and analysis
The data was extracted separately by two independent investiga-
tors. Data were entered into a pre-structured format created on Epi-
info (version 3.2.2) and cross verified by two investigators and
compared for consistency. All inconsistencies were resolved by
referring to the records. The data were analysed in Epi-Info by
complexsampleanalysistoaccountforclustersamplingmethodology
with districts as the primary sampling units. Variables are
summarized by proportions and 95% confidence intervals (95% CI).
Ethical Issues
As this study was a record review of the data collected under
RNTCP, approval was obtained from the Central TB Division,
Ministry of Health and Family Welfare, Govt. of India. The study
protocol was also reviewed and approved by the Ethics Advisory
Group of the International Union Against TB and Lung Disease.
The activity was determined to be a retrospective programme
evaluation of the implementation of national guidelines, hence
Table 1. Diagnosis and standard case definitions used under Revised National Tuberculosis Control Programme.
Disease classification
Pulmonary TB, smear-positive*
NTB in a patient with at least two initial sputum smear examinations (direct smear microscopy) positive for Acid Fast Bacillus (AFB)
N Or: TB in a patient with one sputum smear examination positive for AFB and radiographic abnormalities consistent with active pulmonary TB, as determined by the
treating medical officer
N Or: TB in a patient with one sputum smear specimen positive for AFB and culture-positive for Mycobacterium tuberculosis.
Pulmonary TB, smear-negative
N TB in a patient with symptoms suggestive of TB with at least three sputum smear examinations negative for AFB and radiographic abnormalities consistent with active
pulmonary TB as determined by the treating Medical Officer followed by a decision to treat the patient with a full course of anti-tuberculosis treatment
N Or: diagnosis based on positive culture but negative AFB sputum smear examinations.
Extra-pulmonary TB
Extra-Pulmonary TB is TB of any organ other than the lungs, such as the pleura (TB pleurisy), hilar lymphadenopathy peripheral lymph nodes, intestines, genitourinary
tract, skin, joints and bones, meninges of the brain, etc. Diagnosis should be based on culture-positive specimen from the extra-pulmonary site, histological,
radiological, or strong clinical evidence consistent with active extra-pulmonary TB followed by decision of the treating MO to treat with a full course of anti TB therapy.
A patient diagnosed with both pulmonary and extra-pulmonary TB should be classified as pulmonary TB (e.g., miliary TB)
Type of TB cases
New: A TB patient who has never had treatment for TB or has taken anti-tuberculosis drugs for less than 1 month. A new case can be either sputum positive, sputum
negative or extra-pulmonary.
Relapse: A TB patient who had been declared cured or whose treatment had been completed by a physician, but who reports back to the health service and is now
found to be sputum smear-positive.
Treatment after default: A TB patient who received anti-tuberculosis treatment for at-least 1 month from any source and returns to treatment after having defaulted,
i.e., not taken anti-tuberculosis drugs consecutively for at-least 2 months, and is found to be sputum smear-positive.
Failure: Any TB patient who is smear-positive at 5 months after starting treatment. Failure also includes a patient who was treated with the Category III regimen but
who becomes smear-positive during treatment.
Transferred in: A TB patient who has been received for treatment into a TB Unit after starting treatment in another unit where s/he had been registered
Others: A TB patient who do not fit into the above-mentioned types. Reasons for putting a patient in this type should be specified.
*The following modifications in the case definition have been made since 1st April, 2009.
1. The number of specimen required for diagnosis of smear-positive pulmonary TB is two, with one of them being a morning sputum specimen.
2. One specimen positive out of the two is enough to declare a patient as smear-positive TB.
doi:10.1371/journal.pone.0013338.t001
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databases created for this analysis were stripped of personal health
identifiers and maintained securely.
Results
Demographic and clinical characteristics [Table 3]
Of 1089 TB patients aged ,15 years registered in the 6 selected
districts; treatment cards were available for 1074 patients (98.6%).
There were more female than male children, and the majority of
children were aged 5 years and above with just 11.4% being in the
age group 0–5 years. There were only 7 children less than 1 year
(less than 1% of all patients). Pre-treatment weight was
documented in 99% of patients, and was less than 30 kg in 73%
of the patients. Nearly two-thirds (63.3%) of patients were
diagnosed with programme defined ‘EP- TB’, and peripheral
lymph-node disease (45.6%) was the most common type, followed
by abdominal (13.5%) and pleural TB (11.3%). Most patients
(93.1%) were new (i.e., patients having received no anti-TB
treatment or anti-TB treatment received for less than a month in
the past), with the remainder being re-treatment TB cases (i.e., TB
cases having received more than one month’s anti-TB treatment in
the past). Among the 394 programme defined ‘pulmonary TB
cases’ (which also includes 11 miliary cases), 165 (42%) were
sputum smear-positive (mean age 12 years, standard deviation 2.1
years). Among 72 re-treatment TB patients, 19 had sputum smear-
positive pulmonary TB (classified by RNTCP definitions as
relapse, failure and treatment after default); 13 patients had
sputum smear-negative pulmonary TB and 40 had EPTB (These
smear-negative pulmonary TB and EPTB are classified as per
programme definitions as ‘Retreatment-others’).
Treatment regimens and outcomes at the end of
treatment [Table 4]
Almost all patients (99.5%) were categorised and prescribed
RNTCP standardized short-course chemotherapy regimens. The
Figure 2. Diagnostic algorithm for peripheral lymph node TB.
doi:10.1371/journal.pone.0013338.g002
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new cases (category-1 or category-3), 7.1% of the patients received
the re-treatment regimen (category-2), and the remaining 5 cases
(0.5%) were prescribed either non-rifampicin containing self-
administered regimens or the type of treatment was not recorded.
The type of treatment centre from where the patients received
observed treatment was recorded in 98.5% of the patients, with
the majority of patients (755; 70.3%) receiving treatment from a
government health facility, followed by a community volunteer or
a non-governmental organisation facility. Standard programme
defined treatment outcomes were recorded in in all but 4 patients;
95% of the patients were reported to have been successfully
treated, i.e., completed or cured. Other outcomes [defaulted
(n=28), death (n=12), failure (n=6), transferred out (n=4)] were
noted in 4.3% of the patients. During the study, misclassification of
treatment outcomes in the TB register was identified by the study
investigators in 1.4% (n=13), relative to the treatment cards and
these were corrected during data entry. The median duration of
treatment was 182 days (inter-quartile range 178–187 days) for
patients, whose outcome was ‘treatment completion’ (78 doses)-
with the treatment regimen for new cases (category-1 and
category-3), and 242 days (inter-quartile range 238–256 days) for
patients who completed treatment (102 doses) with the regimen for
retreatment cases (category 2).
Association between Demographic and clinical variables
to treatment outcomes
Program defined treatment outcomes were not significantly
different among sub-groups of patients according to pre-treatment
demographic and clinical variables (Table 5).
Table 2. Treatment categories, Drug dosages and definitions of treatment outcomes.
1: Treatment categories and regiments
Treatment category Type of patients Treatment regimens***
Intensive Phase Continuation phase
Category 1 New sputum smear-positive PTB 2(H3R3Z3E3) 4(H3R3)
New sputum smear-negative PTB, seriously ill*
New extra-PTB, seriously ill*
Category 2 Sputum smear-positive relapse 2(H3R3Z3E3S3)+1(H3R3Z3E3) 5(H3R3E3)
Sputum smear-positive treatment failure
Sputum smear-positive treatment after default
Category 3 New sputum smear-negative, not seriously ill** 2(H3R3Z3) 4(H3R3)
New extra-PTB, not seriously ill**
2: Drug dosages
Weight Bands Isoniazid Rifampicin Pyrazinamide Ethambutol Streptomycin Patient wise box used
,6kgs 10–15 mg/kg 10 mg/kg 30–35 mg/kg 30 mg/kg 15 mg/kg
6–10Kgs 75 mg 75 mg 250 mg 200 mg 15 mg/Kg 1 PC{-13
11–17 Kgs 150 mg 150 mg 500 mg 400 mg 15 mg/Kg 1 PC{-14
18–25 Kgs 225 mg 225 mg 750 mg 600 mg 15 mg/Kg 1 PC-13+1 PC-14
26–30 Kgs 300 mg 300 mg 1000 mg 800 mg 15 mg/Kg 2 PC-14
.30 kgs 600 mg 450 mg 1500 mg 1200 mg 0.75 g Adult boxes
3: Treatment outcomes
Cured: Initially sputum smear-positive patient who has completed treatment and had negative sputum smears, on two occasions, one of which was at the end of
treatment.
Treatment completed: Sputum smear-positive patient who has completed treatment, with negative smears at the end of the intensive phase but none at the end of
treatment. Or: Sputum smear-negative TB patient who has received a full course of treatment and has not become smear-positive during or at the end of treatment.
Or: Extra-pulmonary TB patient who has received a full course of treatment and has not become smear-positive during or at the end of treatment.
Death: Patient who died during the course of treatment regardless of cause
Failure: Any TB patient who is smear positive at 5 months or more after starting treatment. Failure also includes a patient who was treated with Category III regimen
but who becomes smear positive during treatment.
Defaulted: A patient who has not taken anti-TB drugs for 2 months or more consecutively after starting treatment.
Transferred out: A patient who has been transferred to another Tuberculosis Unit/District and his/her treatment outcome is not known.
*In children, seriously ill sputum smear-negative PTB includes all forms of sputum smear-negative PTB other than primary complex. Seriously ill EP-TB includes TB
meningitis (TBM), disseminated TB, TB pericarditis, TB peritonitis and intestinal TB, bilateral extensive pleurisy, spinal TB with or without neurological complications,
genitourinary TB, and bone and joint TB.
**Not seriously ill sputum smear-negative PTB includes primary complex. Not seriously ill EP-TB includes lymph node TB and unilateral pleural effusion.
***Prefix indicates month and subscript indicates thrice weekly.
{PC=Product code. PC-13 is yellow coloured and PC-14 is orange coloured. Mg/kg=milligrams per kilogram body weight.
Sputum smears positive TB patient’s under-go follow-up sputum examinations at the end of intensive phase and extended intensive phase (if IP extended), 2 months
into continuation phase and at the end of treatment.
doi:10.1371/journal.pone.0013338.t002
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kilogram body weight group’’, and 776 patients classified as
‘‘appropriate milligram per kilogram body weight group’’. The
proportion of patients with programme defined treatment
completion rates was 95% (95% CI: 91.6% to 97.8%) in the low
milligrams per kilogram weight group and 96% (95% CI: 94.1%
to 98.4%) in the appropriate milligram per kilogram body weight
group.
Discussion
This study is one of the very few studies that reports data on the
community-wide profile and treatment outcome of TB patients
aged less than 15 years registered and treated under routine
programme conditions in India. Such data are useful to
understand the impact of the programmatic processes and assist
in evidence-based programme policy formulation, planning and
management. The programme defined treatment completion rate
was .95%, which is reassuringly similar to treatment outcomes
reported by other hospital-based studies [24], [25], [26], [27]. This
suggests that the treatment strategy adopted by RNTCP in
treating children with TB disease has been effective In this respect,
the study findings however identifies certain priority areas that
need to be addressed by the National and State health authorities.
First, patients aged less than 5 years constituted only 11% of the
patients in this study despite the fact that rates of childhood TB are
usually considered the highest among those aged 1–4 years [28].
Studies from the tertiary care setting in India have previously
shown that patients aged less than 5 years constituted a much
higher proportion (18–34%) [29] of total childhood TB cases. The
demographic distribution of pediatric TB cases is unusual, and
suggests that many TB patients aged less than 5 years are being
missed by the programme due to non-diagnosis or treatment
outside the programme setting. The reasons for these cases
remaining outside the TB programme are speculative and must be
ascertained in the future. The reasons may include poor access to
Figure 3. Algorithm for clinical monitoring of childhood TB patients.
doi:10.1371/journal.pone.0013338.g003
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or poor access to treatment services. The referral of paediatric
cases, particularly children under 5 years of age, may not be as
effective as it should be because these children may often have
disseminated or severe disease. Paediatricians may often prefer to
keep these children under their care for a more comprehensive
management of their other attendant morbidities which cannot be
managed under the programmatic conditions by the DOT
provider. Further the programme does not provide patient wise
boxes for very small children weighing less than 6 Kg. This further
may be affecting the enrolment of children in the age group of 0–5
years.
Second, the majority of the patients treated had EP-TB and
sputum smear-negative PTB. Only 15% of the patients were
sputum smear-positive; this differs dramatically from adults,
among whom approximately half of notified TB cases have
sputum smear-positive PTB. This is similar to the findings from
other studies [1], [4], [30]. RNTCP currently issues well-defined
diagnostic algorithms for the diagnosis of sputum smear-positive
PTB and TB lymphadenitis, which would have helped in the
diagnosis of about 60% of the children in this study, but guidance
for the diagnosis of pediatric TB for other forms of disease is
limited. With respect to the diagnostic tools, currently, sputum
smear microscopy [31] is the only quality assured diagnostic tool
provided and available under the programme. Other methods for
diagnosing childhood TB using—for example chest radiography
or tuberculin skin-testing are not provided by the programme. The
provision of radiography services are the responsibility of the
respective State Government general health services and not the
RNTCP. In relation to tuberculin skin testing, RNTCP has tried
unsuccessfully to provide a supply of quality assured tuberculin.
There are also no mechanisms existing to assess the quality of chest
radiography or tuberculin test where available and when used.
Under these circumstances, both under-diagnosis (especially in
Table 3. Basic Demographic and clinical characteristics of TB
patients aged ,15 years in Delhi (N=1074).
Characteristics n % (95% CI)
Sex
Female 651 60.6 (54.7–66.3)
Male 420 39.1 (33.2–44.9)
Sex not recorded 3 0.3 (0.06–0.67)
Age Groups
0- to ,1-yrs-old 7 0.7 (0.13–1.18)
1t o,5 yrs-old 115 10.7 (5.9–15.4)
5 to 10 yrs-old 422 39.3 (35.8–42.7)
.10 to ,15 yrs-old 530 49.3 (42.4–56.2)
Pre-treatment RNTCP weight bands
#6 kgs 6 0.6 (0.0–1.1)
.6–10 kgs 84 7.8 (4.2–11.5)
.10–17 kgs 198 18.4 (14.7–22.4)
.17–25 kgs 356 33.1 (29.3–37.6)
.25–30 kgs 139 12.9 (8.6–17.4)
.30kgs 280 26.1 (19.7–30.4)
not recorded 11 1.0 (0.0–2.1)
TB Classification and type
Extra-Pulmonary 680 63.3 (60.5–66.1)
Pulmonary 394 36.7 (33.8–39.4)
Type of TB
New Extra Pulmonary 641 59.7 (56.9–62.4)
New Smear-Negative Pulmonary 213 19.8 (15.5–24.1)
New Smear-Positive Pulmonary 146 13.6 (10.8–16.4)
Re-treatment Others 53 4.9 (4.0–5.8)
Re-treatment Relapse 11 1 (0.08–1.9)
Retreatment ‘Treatment After Default’ 7 0.7 (0.2–1.0)
Re-treatment Failure 1 0.1 (0.0–0.3)
Not recorded 2 0.2 (0.0–0.6)
Extra-Pulmonary TB site (n=680)
Peripheral Lymph nodes 310 45.6 (37.8–53.4)
Abdominal 92 13.5 (6.8–20.1)
Pleural 77 11.3 (6.6–16.0)
Hilar Adenopathy 48 7.1 (2.3–11.7)
Bones/Joints 47 6.9 (3.7–10.0)
Brain/meninges 37 5.4 (3.0–7.8)
Others 36 5.3 (2.2–8.3)
Not recorded 33 4.8 (2.0–7.3)
doi:10.1371/journal.pone.0013338.t003
Table 4. Treatment characteristics and treatment outcomes
of TB patients aged less than 15 years in Delhi (n=1074).
Characteristics n % 95% CI
Treatment category
Cat-1 748 69.6 (62.8–76.5)
Cat-2 76 7.1 (5.5–8.6)
Cat-3 245 22.8 (17.6–28.2)
ND-1* 1 0.1 (0.0–0.3)
ND-2** 1 0.1 (0.0–0.3)
Not recorded 3 0.3 (0.0–0.3)
DOT centre type
Government health facility 755 70.3 (44.1–96.5)
Community Volunteer 167 15.5 (0.0–32.4)
Non Governmental Organisation 120 11.2 (0.7–21.6)
Private practitioner 16 1.5 (0.0–3.8)
Not recorded 16 1.5 (0.5–2.2)
Treatment outcomes
Completed 899 83.7 (79.0–88.3)
Cured*** 121 11.3 (7.4–15.0)
Defaulted 28 2.6 (0.6–4.6)
Death 12 1.1 (0.0–2.3)
Failure 6 0.6 (0.0–1.3)
Transferred Out 4 0.4 (0.0–0.7)
Not recorded 4 0.4 (0.0–1.0)
*ND-1=Treated with Non DOTS regimen-1(2 months Streptomycin(S), isoinazid
(H) and Ethambutol (E) and 10 months of H and E.
**ND-2=Treated with Non DOTS regimen-2(12 months of H and E), ND-1 and
ND-2 regimens are self administered non rifampicin containing regimen) used
in exceptionally few cases.
***Only for pre-treatment smear-positive patients, if they completed the
treatment and were smear-negative at the end of treatment and one other
occasion during the course of treatment.
doi:10.1371/journal.pone.0013338.t004
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studies have shown that the diagnostic misclassification can be up
to 15%–20% in children seeking health care in high TB-incidence
communities with limited quality assured diagnostic tools [32],
[33]. These findings suggest that the RNTCP should, in
consultation with the relevant professional bodies, urgently make
additional efforts to further develop algorithms and criteria for
diagnosis and management of childhood TB within programmatic
framework, particularly EP-TB beyond lymphadenitis. This will
hopefully increase the confidence of the treating medical
practitioners on the programme which may increase the number
of TB cases (especially among very young children) notified to the
programme.
Third, the programme defined treatment outcome ‘treatment
completion’ is based on programmatic end points and not on
the basis of well defined clinical criteria. The usage of
programmatic terminology for reported treatment outcomes
such as ‘‘completion’’ might be misleading when compared to
clinical trial conditions. Whilst under clinical trial conditions, a
successful response to treatment is validated against pre-
specified criteria, what the programme terms as treatment
completion is not subject to standardized validation. It is
possible that some providers reported treatment as ‘completed’
on the basis of drug consumption, and may not have sufficiently
assessed clinical response to treatment. The programme must
consider outlining further clinical response criteria for charac-
Table 5. Association between demographic and clinical characteristics with treatment completion for TB patients aged ,15 years
in Delhi.
Demographic and clinical characteristics Programme specified treatment outcome*
Treatment completed Other
n % 95%CI n % Total
Sex (n=1071)
Female 614 94% (90.7–97.9) 37 6% 651
Male 403 96% (93.4–98.4) 17 4% 420
Age (in years)[n=1074]
,5 years 154 96% (90.6–99.5) 6 4% 160
$5 to 10 years 367 96% (93.8–98.1) 17 4% 384
.10 to ,15 years 499 94% (91.0–97.2) 31 6% 530
RNTCP pre treatment weight bands [n=1063]
#10 Kgs 85 95% (88.0–100) 5 5% 90
.10–17 Kgs 189 95% (89.9–100) 9 5% 198
.17–25 kgs 339 95% (92.8–97.6) 17 5% 356
.25–30 kgs 130 94% (89.8–97.2) 9 6% 139
.30 kgs 270 96% (93.3–99.5) 10 4% 280
TB Classification [n=1074]
Extra-Pulmonary 655 96% (94.1–98.5) 25 4% 680
Pulmonary 365 93% (88.8–96.4) 29 7% 394
Type of TB [n=1072]
New Extra Pulmonary 621 97% (94.6–99.1) 20 3% 641
New Smear-Negative 201 94% (88.7–100.0) 12 6% 213
New Smear-Positive 134 92% (89.0–94.5) 12 8% 146
Re-treatment Others 48 91% (82.3–98.8) 5 9% 53
Re-treatment Smear-Positive 16 84% (60.1–100) 3 16% 19
Extra-Pulmonary TB site [n=647]
Peripheral Lymph node 302 97% (94.8–100) 8 3% 310
Other sites 326 97% (94.6–98.8) 11 3% 337
DOT centre type [n=1059]
Government health facility 718 95% (91.8–98.3) 37 5% 755
Other DOT providers 291 96% (92.6–98.8) 13 4% 304
Treatment category [n=1069]
Cat-1 713 95% (92.9–97.7) 35 5% 748
Cat-2 68 89% (80.8–98.0) 8 11% 76
Cat-3 237 97% (92.9–100) 8 3% 245
*‘Treatment completed’ also includes sputum positive patients who were declared as cured and ‘others’ includes deaths, default, failures, transferred out and not-
recorded.
doi:10.1371/journal.pone.0013338.t005
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completion’.
Fourth, the programme defined treatment completion rates
were similar among those treated with doses that were less than or
in accordance the WHO recommendations. The anti-TB drug
dosages and the regimens were formulated by RNTCP in
consultation with the Indian Academy of Pediatricians, based on
the treatment guidelines recommended by WHO in 2003 [9] [2].
However, WHO subsequently increased the dosages per kilogram
recommended for children in its later revision of the treatment
guidelines [19], [20], [34]. Concerns have been raised about
under-dosing of children whose pre-treatment weight is at the
higher end of the individual RNTCP pre-treatment weight bands
(e.g, 9–10 kgs, 16–17 kgs, 24–25 kgs, 29–30 Kgs) [18] [12]. Our
study shows that programme defined treatment completion rates
were not different between those on the high end of the weight
band with lower milligrams per kilogram dosing than currently
recommended, as compared to those patients treated with WHO-
recommended dosing. This finding, however, needs validation
using more robust diagnostic and clinical outcome criteria and
longer term follow-up, which is not routinely feasible in
programme settings.
Lastly, In Delhi being a low HIV prevalence state (General
Population prevalence of 0.25% [35]), the routine offer of
counselling, voluntary testing of HIV status and recording of the
status of HIV infection on the programme records for all TB
patients was not the policy in 2008. Hence we could not ascertain
the HIV status of this study cohort from the records. The
programme has, however, revised its policy in 2009, including
Delhi into the list of states in the country where counselling,
voluntary testing and recording of HIV status on programme
records for all TB patients has become a routine activity. The
programme must use the opportunity provided by this revised
policy to assess the relative contribution of HIV infection to
paediatric notifications in Delhi.
Limitations of the study
First, the study was retrospective in nature, and record keeping
may have been sub-optimal. However, since the programme is
supervised and monitored rigorously by programme managers and
staff from multiple levels which includes periodic data validation
and accuracy checks according to programme guidelines [36], we
feel that major inaccuracies are unlikely.
Second, in this retrospective record review, we could not
evaluate the validity of the diagnosis, or the adequacy of therapy at
the end of treatment and long term treatment outcomes. Since the
majority of patients had EP-TB and sputum smear-negative PTB,
there are possibilities of misclassification of TB diagnosis and
treatment outcomes. However, since Delhi is an urban centre with
many tertiary care hospitals and as most of the childhood TB
patients based on the programmatic observation are diagnosed by
pediatricians and referred to the programme for treatment, the
extent of misclassification of TB diagnosis, if any, will most likely
be insignificant.
Furthermore, the sample size in our study may not have been
large enough to have sufficient power to detect significant
differences among different demographic and clinical subgroups.
However, such small differences are not likely to be programmat-
ically significant.
Conclusions and recommendations
As measured by programme defined treatment outcomes,
childhood TB patients in Delhi, across all groups notified under
the RNTCP which follows WHO TB treatment guideline
definitions, have high treatment completion rates. The demo-
graphic and clinical profile of registered childhood TB patients
shows that they are mostly aged 5–15 years and with programme
defined non-serious forms of TB. Further studies are needed to
assess i) the reasons for the low proportion of under 5 years of age
TB case notifications, identify and implement strategies to reach
out to the cases missed by the programme and ii) the accuracy of
diagnosis and treatment clinical response in various demographic
and clinical subgroups, especially when programmatic definitions
of ‘treatment completion’ are used.
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